Marc Tessier-Lavigne
CIK 1437435 · EVP, RESEARCH DRUG DISCOVERY · last filed 2025-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$49.17M
Companies
6
Total Filings
63
Lifetime Open-Market Net
-$93.00M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DNLI | Director | 1,965,424 | $24.12 | $47.41M | -$36.87M | 25 | 2025-06-05 |
| REGN | Director | 2,434 | $723.26 | $1.76M | -$54.63M | 25 | 2023-01-05 |
| AGIO | Director | — | $32.71 | — | $0 | 3 | 2016-06-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 250,000 | — | — | $0 | 3 | 2016-06-21 |
| PFE | Director | — | $24.89 | — | $0 | 4 | 2015-04-24 |
| DNA | EVP, RESEARCH DRUG DISCOVERY | 29 | $7.93 | $230 | -$1.50M | 1 | 2008-07-18 |
Recent Filings · Page 3 of 7
63 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-12-10 | REGN | Mixed | — | -$1.11M | EDGAR |
| 2021-09-15 | REGN | Mixed | — | -$4.69M | EDGAR |
| 2021-06-08 | DNLI | Mixed | — | -$4.87M | EDGAR |
| 2021-06-04 | DNLI | Grant (A) | +2,074 | $0 | EDGAR |
| 2021-05-24 | DNLI | Sell (S) | −46,763 | -$2.81M | EDGAR |
| 2021-05-05 | DNLI | Sell (S) | −3,237 | -$194.6K | EDGAR |
| 2021-04-05 | DNLI | Sell (S) | −50,000 | -$2.83M | EDGAR |
| 2021-03-03 | DNLI | Sell (S) | −100,000 | -$6.62M | EDGAR |
| 2021-01-05 | REGN | Grant (A) | +248 | $0 | EDGAR |
| 2020-06-18 | DNLI | Sell (S) | −400,000 | -$10.44M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.